nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—peripheral nervous system neoplasm	0.254	0.493	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Tretinoin—peripheral nervous system neoplasm	0.07	0.136	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Tretinoin—peripheral nervous system neoplasm	0.0488	0.0947	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.0305	0.0593	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—peripheral nervous system neoplasm	0.0295	0.0571	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0284	0.0551	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Cisplatin—peripheral nervous system neoplasm	0.0209	0.0406	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.013	0.0253	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0119	0.0232	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00815	0.0158	CbGbCtD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—peripheral nervous system neoplasm	0.00354	0.592	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00244	0.408	CbGdCrCtD
Medroxyprogesterone Acetate—Drospirenone—BCHE—peripheral nervous system neoplasm	0.0011	0.392	CrCbGaD
Medroxyprogesterone Acetate—Megestrol acetate—ABCB1—peripheral nervous system neoplasm	0.000491	0.176	CrCbGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000489	0.00602	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—TH—peripheral nervous system neoplasm	0.000484	0.00596	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—BIRC5—peripheral nervous system neoplasm	0.000449	0.00553	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.000447	0.00551	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000442	0.00544	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TH—peripheral nervous system neoplasm	0.000422	0.0052	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TH—peripheral nervous system neoplasm	0.000416	0.00512	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Nuclear signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000382	0.00471	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—IFNB1—peripheral nervous system neoplasm	0.000378	0.00466	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.000376	0.00464	CbGpPWpGaD
Medroxyprogesterone Acetate—Methylprednisolone—ABCB1—peripheral nervous system neoplasm	0.000376	0.135	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—IFNB1—peripheral nervous system neoplasm	0.000372	0.00459	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000367	0.00452	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.000344	0.00424	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.000342	0.00421	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Corticotropin-releasing hormone—AKT1—peripheral nervous system neoplasm	0.000327	0.00402	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.000323	0.00398	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000323	0.00398	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—GNS—peripheral nervous system neoplasm	0.000319	0.00393	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000315	0.00388	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000312	0.00385	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—NME1—peripheral nervous system neoplasm	0.000306	0.00377	CbGpPWpGaD
Medroxyprogesterone Acetate—Spironolactone—ABCB1—peripheral nervous system neoplasm	0.000306	0.109	CrCbGaD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000298	0.00367	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000298	0.00367	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—COX2—peripheral nervous system neoplasm	0.000295	0.00363	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000289	0.00356	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000288	0.00355	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—CDKN2A—peripheral nervous system neoplasm	0.000287	0.00353	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Nongenotropic Androgen signaling—HRAS—peripheral nervous system neoplasm	0.000262	0.00323	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.000249	0.00307	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Validated nuclear estrogen receptor alpha network—MYC—peripheral nervous system neoplasm	0.000245	0.00302	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000239	0.00295	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000239	0.00294	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000235	0.00289	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Nongenotropic Androgen signaling—AKT1—peripheral nervous system neoplasm	0.000232	0.00285	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—peripheral nervous system neoplasm	0.000231	0.00284	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000227	0.00279	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Estrogen signaling pathway—AKT1—peripheral nervous system neoplasm	0.000226	0.00279	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000223	0.00274	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—EED—peripheral nervous system neoplasm	0.000221	0.00273	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—NRAS—peripheral nervous system neoplasm	0.000221	0.00272	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000219	0.0027	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000219	0.0027	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000218	0.00269	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000218	0.00269	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000206	0.00254	CbGpPWpGaD
Medroxyprogesterone Acetate—Hydrocortisone—ABCB1—peripheral nervous system neoplasm	0.000203	0.0727	CrCbGaD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000202	0.00248	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000201	0.00248	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.0002	0.00246	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—MYC—peripheral nervous system neoplasm	0.000198	0.00244	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000198	0.00244	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000197	0.00242	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000196	0.00242	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000195	0.0024	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—ENO2—peripheral nervous system neoplasm	0.000194	0.00238	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	0.000192	0.00236	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—GNS—peripheral nervous system neoplasm	0.000188	0.00232	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000188	0.00231	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000184	0.00227	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000181	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—ERBB2—peripheral nervous system neoplasm	0.000179	0.0022	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000178	0.0022	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000177	0.00218	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000173	0.00213	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—EED—peripheral nervous system neoplasm	0.000169	0.00208	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000168	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—Progesterone—ABCB1—peripheral nervous system neoplasm	0.000165	0.0592	CrCbGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—BCHE—peripheral nervous system neoplasm	0.000163	0.00201	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—TP53—peripheral nervous system neoplasm	0.000163	0.002	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—HRAS—peripheral nervous system neoplasm	0.000162	0.00199	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GNS—peripheral nervous system neoplasm	0.000158	0.00194	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—peripheral nervous system neoplasm	0.000156	0.00193	CbGpPWpGaD
Medroxyprogesterone Acetate—Testosterone—ABCB1—peripheral nervous system neoplasm	0.000156	0.056	CrCbGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000156	0.00192	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.000155	0.00191	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000154	0.0019	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—TH—peripheral nervous system neoplasm	0.000154	0.00189	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000151	0.00186	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—NME1—peripheral nervous system neoplasm	0.000151	0.00186	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000147	0.00181	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—COX2—peripheral nervous system neoplasm	0.000146	0.00179	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Validated nuclear estrogen receptor alpha network—MYC—peripheral nervous system neoplasm	0.000144	0.00177	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—AKT1—peripheral nervous system neoplasm	0.000143	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000138	0.0017	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—MYC—peripheral nervous system neoplasm	0.000137	0.00169	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000135	0.00166	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Coregulation of Androgen receptor activity—AKT1—peripheral nervous system neoplasm	0.000135	0.00166	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000134	0.00165	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—peripheral nervous system neoplasm	0.000133	0.00163	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000132	0.00163	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000132	0.00162	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.000132	0.00162	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PPP3R1—peripheral nervous system neoplasm	0.000132	0.00162	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—EED—peripheral nervous system neoplasm	0.00013	0.0016	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.000129	0.00159	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—EED—peripheral nervous system neoplasm	0.000128	0.00158	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000126	0.00156	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—GNAS—peripheral nervous system neoplasm	0.000125	0.00155	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000123	0.00152	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000121	0.00148	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.000119	0.00147	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.000117	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000117	0.00145	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ENO2—peripheral nervous system neoplasm	0.000114	0.00141	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.000112	0.00138	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—AP-1 transcription factor network—TP53—peripheral nervous system neoplasm	0.00011	0.00136	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.00011	0.00135	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—AP-1 transcription factor network—TP53—peripheral nervous system neoplasm	0.000108	0.00134	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	0.000107	0.00132	CbGpPWpGaD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.000106	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Doxorubicin—peripheral nervous system neoplasm	0.000106	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000106	0.000268	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000105	0.000267	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000104	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000104	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000104	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000104	0.00128	CbGpPWpGaD
Medroxyprogesterone Acetate—Weight decreased—Epirubicin—peripheral nervous system neoplasm	0.000104	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000104	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Etoposide—peripheral nervous system neoplasm	0.000103	0.000262	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000103	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000102	0.00126	CbGpPWpGaD
Medroxyprogesterone Acetate—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000102	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Bronchitis—Doxorubicin—peripheral nervous system neoplasm	0.000102	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000102	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000102	0.00125	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000101	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000101	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.0001	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.0001	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Etoposide—peripheral nervous system neoplasm	0.0001	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000253	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.0001	0.00123	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	9.99e-05	0.00123	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CD55—peripheral nervous system neoplasm	9.97e-05	0.00123	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	9.96e-05	0.00123	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Androgen receptor signaling pathway—AKT1—peripheral nervous system neoplasm	9.96e-05	0.00123	CbGpPWpGaD
Medroxyprogesterone Acetate—Jaundice—Epirubicin—peripheral nervous system neoplasm	9.95e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Epirubicin—peripheral nervous system neoplasm	9.95e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Etoposide—peripheral nervous system neoplasm	9.93e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	9.92e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Doxorubicin—peripheral nervous system neoplasm	9.9e-05	0.000251	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	9.84e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Alitretinoin—peripheral nervous system neoplasm	9.84e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Vincristine—peripheral nervous system neoplasm	9.81e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Epirubicin—peripheral nervous system neoplasm	9.78e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	9.78e-05	0.000248	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	9.65e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	9.65e-05	0.00119	CbGpPWpGaD
Medroxyprogesterone Acetate—Weight increased—Doxorubicin—peripheral nervous system neoplasm	9.64e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Epirubicin—peripheral nervous system neoplasm	9.62e-05	0.000244	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Doxorubicin—peripheral nervous system neoplasm	9.58e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Epirubicin—peripheral nervous system neoplasm	9.57e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	9.57e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ENO2—peripheral nervous system neoplasm	9.56e-05	0.00118	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—peripheral nervous system neoplasm	9.55e-05	0.00118	CbGpPWpGaD
Medroxyprogesterone Acetate—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	9.55e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Dactinomycin—peripheral nervous system neoplasm	9.53e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	9.51e-05	0.00117	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	9.49e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Vincristine—peripheral nervous system neoplasm	9.48e-05	0.00024	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Alitretinoin—peripheral nervous system neoplasm	9.46e-05	0.00024	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	9.44e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Doxorubicin—peripheral nervous system neoplasm	9.44e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Doxorubicin—peripheral nervous system neoplasm	9.44e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	9.41e-05	0.00116	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Alitretinoin—peripheral nervous system neoplasm	9.38e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	9.37e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	9.34e-05	0.000237	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Epirubicin—peripheral nervous system neoplasm	9.33e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Alitretinoin—peripheral nervous system neoplasm	9.32e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	9.28e-05	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—peripheral nervous system neoplasm	9.26e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	9.22e-05	0.00114	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Etoposide—peripheral nervous system neoplasm	9.22e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	9.21e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—peripheral nervous system neoplasm	9.2e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—SLC2A1—peripheral nervous system neoplasm	9.2e-05	0.00113	CbGpPWpGaD
Medroxyprogesterone Acetate—Body temperature increased—Etoposide—peripheral nervous system neoplasm	9.18e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Etoposide—peripheral nervous system neoplasm	9.18e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	9.18e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—peripheral nervous system neoplasm	9.16e-05	0.000232	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	9.16e-05	0.000232	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Vincristine—peripheral nervous system neoplasm	9.11e-05	0.000231	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Cisplatin—peripheral nervous system neoplasm	9.09e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	9.09e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PPIP5K2—peripheral nervous system neoplasm	9.08e-05	0.00112	CbGpPWpGaD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—peripheral nervous system neoplasm	9.05e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	9.05e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Vincristine—peripheral nervous system neoplasm	9.04e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Vincristine—peripheral nervous system neoplasm	9.03e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	9.02e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	9e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	8.98e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Vincristine—peripheral nervous system neoplasm	8.98e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	8.93e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	8.91e-05	0.0011	CbGpPWpGaD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	8.91e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—peripheral nervous system neoplasm	8.86e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Alitretinoin—peripheral nervous system neoplasm	8.83e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—peripheral nervous system neoplasm	8.83e-05	0.000224	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	8.8e-05	0.00108	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	8.67e-05	0.00022	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—peripheral nervous system neoplasm	8.66e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	8.63e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—peripheral nervous system neoplasm	8.56e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	8.55e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—peripheral nervous system neoplasm	8.54e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	8.52e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	8.52e-05	0.00105	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Vincristine—peripheral nervous system neoplasm	8.51e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	8.5e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	8.48e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	8.48e-05	0.000215	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	8.47e-05	0.00104	CbGpPWpGaD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	8.41e-05	0.000213	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	8.37e-05	0.000212	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	8.35e-05	0.000212	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Etoposide—peripheral nervous system neoplasm	8.33e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	8.33e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—peripheral nervous system neoplasm	8.31e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	8.31e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	8.27e-05	0.00021	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	8.27e-05	0.00102	CbGpPWpGaD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	8.26e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—peripheral nervous system neoplasm	8.22e-05	0.000208	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—peripheral nervous system neoplasm	8.21e-05	0.000208	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—peripheral nervous system neoplasm	8.17e-05	0.000207	CcSEcCtD
Medroxyprogesterone Acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	8.15e-05	0.001	CbGpPWpGaD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—peripheral nervous system neoplasm	8.09e-05	0.000205	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—BCHE—peripheral nervous system neoplasm	8.08e-05	0.000995	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Glucocorticoid receptor regulatory network—AKT1—peripheral nervous system neoplasm	8.07e-05	0.000994	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Cisplatin—peripheral nervous system neoplasm	8.06e-05	0.000204	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—peripheral nervous system neoplasm	8.03e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—peripheral nervous system neoplasm	8.01e-05	0.000203	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Cisplatin—peripheral nervous system neoplasm	7.99e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Cisplatin—peripheral nervous system neoplasm	7.98e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—peripheral nervous system neoplasm	7.97e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—peripheral nervous system neoplasm	7.97e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—peripheral nervous system neoplasm	7.94e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—peripheral nervous system neoplasm	7.92e-05	0.000201	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—peripheral nervous system neoplasm	7.9e-05	0.0002	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—VIP—peripheral nervous system neoplasm	7.88e-05	0.000971	CbGpPWpGaD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	7.87e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—peripheral nervous system neoplasm	7.86e-05	0.000199	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—peripheral nervous system neoplasm	7.83e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	7.81e-05	0.000198	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	7.8e-05	0.00096	CbGpPWpGaD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—peripheral nervous system neoplasm	7.75e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	7.74e-05	0.000953	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	7.73e-05	0.000952	CbGpPWpGaD
Medroxyprogesterone Acetate—Back pain—Epirubicin—peripheral nervous system neoplasm	7.71e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—SLC2A1—peripheral nervous system neoplasm	7.7e-05	0.000949	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	7.69e-05	0.000947	CbGpPWpGaD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	7.69e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—peripheral nervous system neoplasm	7.68e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—peripheral nervous system neoplasm	7.67e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	7.66e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	7.64e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—peripheral nervous system neoplasm	7.61e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—TH—peripheral nervous system neoplasm	7.59e-05	0.000935	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Cisplatin—peripheral nervous system neoplasm	7.53e-05	0.000191	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—peripheral nervous system neoplasm	7.49e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	7.43e-05	0.000188	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	7.4e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.39e-05	0.00091	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Etoposide—peripheral nervous system neoplasm	7.38e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	7.38e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—peripheral nervous system neoplasm	7.38e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—peripheral nervous system neoplasm	7.37e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—peripheral nervous system neoplasm	7.33e-05	0.000186	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—peripheral nervous system neoplasm	7.32e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—peripheral nervous system neoplasm	7.31e-05	0.000185	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	7.28e-05	0.000896	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Etoposide—peripheral nervous system neoplasm	7.27e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—peripheral nervous system neoplasm	7.27e-05	0.000184	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	7.25e-05	0.000893	CbGpPWpGaD
Medroxyprogesterone Acetate—Tension—Doxorubicin—peripheral nervous system neoplasm	7.24e-05	0.000183	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	7.23e-05	0.000183	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—peripheral nervous system neoplasm	7.19e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—peripheral nervous system neoplasm	7.17e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—peripheral nervous system neoplasm	7.16e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—peripheral nervous system neoplasm	7.15e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—peripheral nervous system neoplasm	7.14e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—peripheral nervous system neoplasm	7.09e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—peripheral nervous system neoplasm	7.05e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.000178	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	6.93e-05	0.000853	CbGpPWpGaD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—peripheral nervous system neoplasm	6.91e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—peripheral nervous system neoplasm	6.9e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	6.85e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—peripheral nervous system neoplasm	6.82e-05	0.000173	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—peripheral nervous system neoplasm	6.79e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—peripheral nervous system neoplasm	6.79e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—peripheral nervous system neoplasm	6.79e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—peripheral nervous system neoplasm	6.78e-05	0.000172	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—peripheral nervous system neoplasm	6.77e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	6.74e-05	0.000171	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—peripheral nervous system neoplasm	6.71e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—peripheral nervous system neoplasm	6.65e-05	0.000169	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—peripheral nervous system neoplasm	6.64e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—peripheral nervous system neoplasm	6.63e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—peripheral nervous system neoplasm	6.62e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—peripheral nervous system neoplasm	6.56e-05	0.000166	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	6.52e-05	0.000804	CbGpPWpGaD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—peripheral nervous system neoplasm	6.52e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	6.51e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—peripheral nervous system neoplasm	6.51e-05	0.000165	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	6.49e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—peripheral nervous system neoplasm	6.47e-05	0.000164	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Epirubicin—peripheral nervous system neoplasm	6.4e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	6.4e-05	0.000789	CbGpPWpGaD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—peripheral nervous system neoplasm	6.39e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	6.38e-05	0.000162	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	6.37e-05	0.000161	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—peripheral nervous system neoplasm	6.35e-05	0.000161	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—peripheral nervous system neoplasm	6.32e-05	0.00016	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	6.29e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—peripheral nervous system neoplasm	6.28e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—peripheral nervous system neoplasm	6.28e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	6.28e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—peripheral nervous system neoplasm	6.26e-05	0.000159	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	6.24e-05	0.000158	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—peripheral nervous system neoplasm	6.21e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—peripheral nervous system neoplasm	6.2e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—GNAS—peripheral nervous system neoplasm	6.2e-05	0.000763	CbGpPWpGaD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	6.14e-05	0.000156	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HSD17B12—peripheral nervous system neoplasm	6.13e-05	0.000756	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	6.11e-05	0.000752	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ABCB1—peripheral nervous system neoplasm	6.08e-05	0.000749	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—peripheral nervous system neoplasm	6.08e-05	0.000154	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—peripheral nervous system neoplasm	6.07e-05	0.000154	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—peripheral nervous system neoplasm	6.02e-05	0.000153	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	6.01e-05	0.00074	CbGpPWpGaD
Medroxyprogesterone Acetate—Infection—Doxorubicin—peripheral nervous system neoplasm	5.98e-05	0.000152	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	5.95e-05	0.000733	CbGpPWpGaD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	5.93e-05	0.00015	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KNG1—peripheral nervous system neoplasm	5.93e-05	0.00073	CbGpPWpGaD
Medroxyprogesterone Acetate—Shock—Doxorubicin—peripheral nervous system neoplasm	5.92e-05	0.00015	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	5.91e-05	0.00015	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	5.9e-05	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	5.88e-05	0.000149	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	5.85e-05	0.000721	CbGpPWpGaD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	5.85e-05	0.000148	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	5.84e-05	0.000148	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	5.82e-05	0.000148	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	5.8e-05	0.000147	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—peripheral nervous system neoplasm	5.79e-05	0.000147	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—peripheral nervous system neoplasm	5.74e-05	0.000145	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	5.73e-05	0.000145	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	5.66e-05	0.000697	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	5.66e-05	0.000143	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	5.65e-05	0.000696	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—peripheral nervous system neoplasm	5.63e-05	0.000143	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	5.62e-05	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—peripheral nervous system neoplasm	5.61e-05	0.000142	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—peripheral nervous system neoplasm	5.57e-05	0.000141	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	5.49e-05	0.000139	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	5.47e-05	0.000673	CbGpPWpGaD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000138	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	5.41e-05	0.000137	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.41e-05	0.000666	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	5.37e-05	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	5.36e-05	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—peripheral nervous system neoplasm	5.35e-05	0.000136	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	5.32e-05	0.000135	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	5.3e-05	0.000134	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	5.23e-05	0.000133	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	5.2e-05	0.000132	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—peripheral nervous system neoplasm	5.19e-05	0.000132	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—GNAS—peripheral nervous system neoplasm	5.18e-05	0.000638	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—peripheral nervous system neoplasm	5.17e-05	0.000131	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—peripheral nervous system neoplasm	5.15e-05	0.00013	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.00013	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	5.14e-05	0.00013	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTPN11—peripheral nervous system neoplasm	5.14e-05	0.000633	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	5.1e-05	0.000628	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	5.08e-05	0.000626	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	5.03e-05	0.000619	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	5e-05	0.000616	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.99e-05	0.000615	CbGpPWpGaD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	4.96e-05	0.000126	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	4.93e-05	0.000607	CbGpPWpGaD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	4.92e-05	0.000125	CcSEcCtD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	4.87e-05	0.0006	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	4.79e-05	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—peripheral nervous system neoplasm	4.78e-05	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	4.76e-05	0.000121	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KNG1—peripheral nervous system neoplasm	4.67e-05	0.000576	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—peripheral nervous system neoplasm	4.67e-05	0.000118	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	4.63e-05	0.00057	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—peripheral nervous system neoplasm	4.6e-05	0.000117	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	4.46e-05	0.000549	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	4.45e-05	0.000113	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	4.44e-05	0.000112	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GNS—peripheral nervous system neoplasm	4.44e-05	0.000546	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—peripheral nervous system neoplasm	4.32e-05	0.000109	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—peripheral nervous system neoplasm	4.3e-05	0.000109	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	4.27e-05	0.000526	CbGpPWpGaD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—peripheral nervous system neoplasm	4.26e-05	0.000108	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NME1—peripheral nervous system neoplasm	4.25e-05	0.000524	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	4.16e-05	0.000513	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.15e-05	0.000511	CbGpPWpGaD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—peripheral nervous system neoplasm	4.14e-05	0.000105	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	4.12e-05	0.000104	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Epirubicin—peripheral nervous system neoplasm	4.1e-05	0.000104	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—peripheral nervous system neoplasm	4.1e-05	0.000104	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—COX2—peripheral nervous system neoplasm	4.09e-05	0.000504	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GNAS—peripheral nervous system neoplasm	4.09e-05	0.000503	CbGpPWpGaD
Medroxyprogesterone Acetate—Headache—Epirubicin—peripheral nervous system neoplasm	4.08e-05	0.000103	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB2—peripheral nervous system neoplasm	4.06e-05	0.000501	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—peripheral nervous system neoplasm	3.98e-05	0.000101	CcSEcCtD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	3.87e-05	0.000477	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Epirubicin—peripheral nervous system neoplasm	3.87e-05	9.8e-05	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—peripheral nervous system neoplasm	3.83e-05	9.7e-05	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—peripheral nervous system neoplasm	3.8e-05	9.62e-05	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	3.79e-05	9.61e-05	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—peripheral nervous system neoplasm	3.77e-05	9.56e-05	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GNS—peripheral nervous system neoplasm	3.61e-05	0.000445	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	3.6e-05	0.000444	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—peripheral nervous system neoplasm	3.58e-05	9.06e-05	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NME1—peripheral nervous system neoplasm	3.46e-05	0.000426	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—AKT1—peripheral nervous system neoplasm	3.39e-05	0.000417	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—COX2—peripheral nervous system neoplasm	3.33e-05	0.00041	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	3.29e-05	0.000406	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.21e-05	0.000395	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NRAS—peripheral nervous system neoplasm	3.09e-05	0.000381	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	2.98e-05	0.000367	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	2.94e-05	0.000362	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—peripheral nervous system neoplasm	2.88e-05	0.000355	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.85e-05	0.000351	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.84e-05	0.00035	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	2.74e-05	0.000338	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ENO2—peripheral nervous system neoplasm	2.69e-05	0.000331	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	2.61e-05	0.000322	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.58e-05	0.000318	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—peripheral nervous system neoplasm	2.45e-05	0.000301	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.4e-05	0.000295	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	2.38e-05	0.000293	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	2.28e-05	0.000281	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—BCHE—peripheral nervous system neoplasm	2.27e-05	0.00028	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HRAS—peripheral nervous system neoplasm	2.26e-05	0.000279	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	2.25e-05	0.000277	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	2.2e-05	0.000271	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO2—peripheral nervous system neoplasm	2.19e-05	0.000269	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.17e-05	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NRAS—peripheral nervous system neoplasm	2.17e-05	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TH—peripheral nervous system neoplasm	2.13e-05	0.000263	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CASP3—peripheral nervous system neoplasm	2.04e-05	0.000251	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.02e-05	0.000248	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—AKT1—peripheral nervous system neoplasm	2e-05	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—peripheral nervous system neoplasm	1.86e-05	0.00023	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—BCHE—peripheral nervous system neoplasm	1.85e-05	0.000228	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.76e-05	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GNAS—peripheral nervous system neoplasm	1.74e-05	0.000215	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TH—peripheral nervous system neoplasm	1.74e-05	0.000214	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ABCB1—peripheral nervous system neoplasm	1.71e-05	0.000211	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.71e-05	0.00021	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—AKT1—peripheral nervous system neoplasm	1.7e-05	0.000209	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—AKT1—peripheral nervous system neoplasm	1.67e-05	0.000206	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.67e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.66e-05	0.000204	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.59e-05	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.58e-05	0.000195	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	1.44e-05	0.000178	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—peripheral nervous system neoplasm	1.44e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GNAS—peripheral nervous system neoplasm	1.42e-05	0.000175	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—peripheral nervous system neoplasm	1.41e-05	0.000174	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.4e-05	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ABCB1—peripheral nervous system neoplasm	1.39e-05	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.32e-05	0.000162	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—peripheral nervous system neoplasm	1.31e-05	0.000161	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—AKT1—peripheral nervous system neoplasm	1.29e-05	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HRAS—peripheral nervous system neoplasm	1.25e-05	0.000154	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	1.22e-05	0.00015	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.2e-05	0.000147	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.16e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	1.15e-05	0.000141	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—AKT1—peripheral nervous system neoplasm	1.1e-05	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1e-05	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—AKT1—peripheral nervous system neoplasm	9.96e-06	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—AKT1—peripheral nervous system neoplasm	9.81e-06	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	9.35e-06	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	9.34e-06	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	9.18e-06	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	7.67e-06	9.45e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	7.33e-06	9.03e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	6.48e-06	7.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—AKT1—peripheral nervous system neoplasm	4.7e-06	5.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—AKT1—peripheral nervous system neoplasm	3.83e-06	4.71e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	2.52e-06	3.11e-05	CbGpPWpGaD
